![Parisa Zamiri](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Parisa Zamiri
No open positions remaining
Profile
Parisa Zamiri is currently the Chief Medical Officer at Opthea Ltd. She previously held positions as the Director-Pre-Clinical Sciences at Arsenal Medical, Inc. from 2007 to 2011, the Chief Medical Officer at Graybug Vision, Inc. from 2020 to 2023, and the VP & Global Head-Clinical Development at Novartis AG from 2012 to 2020.
She also served as the Chief Medical Officer at CalciMedica, Inc. and Complement Therapeutics Ltd. Dr. Zamiri holds a doctorate degree from University College London and a graduate degree from King's College London.
Former positions of Parisa Zamiri
| Companies | Position | End |
|---|---|---|
| OPTHEA LIMITED | Chief Tech/Sci/R&D Officer | 2025-07-14 |
| CALCIMEDICA, INC. | Chief Tech/Sci/R&D Officer | 2023-02-27 |
| CALCIMEDICA, INC. | Chief Tech/Sci/R&D Officer | 2023-02-27 |
| NOVARTIS AG | Corporate Officer/Principal | 2020-05-31 |
Arsenal Medical, Inc.
 Arsenal Medical, Inc. Medical SpecialtiesHealth Technology Develops biomaterials provides local therapy for important medical conditions across therapeutic areas | Corporate Officer/Principal | 2011-10-31 |
Training of Parisa Zamiri
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
52
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Arsenal Medical, Inc.
Arsenal Medical, Inc. Medical SpecialtiesHealth Technology Develops biomaterials provides local therapy for important medical conditions across therapeutic areas | Health Technology |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, which focuses on developing transformative medicines for the treatment of chronic diseases of retina and optic nerve | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Opthea Ltd.
 Opthea Ltd. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for treatment retinal diseases | Health Technology |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops complement medicines | Health Technology |
CalciMedica, Inc.
 CalciMedica, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
- Stock Market
- Insiders
- Parisa Zamiri
